Insider Trading June 24, 2026 04:15 PM

Core Scientific Legal Officer Executes $292,939 Stock Sale Under Pre-Arranged Plan

Todd DuChene's transaction follows a significant 139% one-year rally for CORZ, while analysts highlight growth in power capacity and AI colocation potential amid noted valuation and volatility concerns.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
CORZ

Core Scientific, Inc. (CORZ) Chief Legal and Administrative Officer Todd M. DuChene sold 10,000 shares of common stock on June 22, 2026, totaling approximately $292,939. The sales were executed under a Rule 10b5-1 trading plan adopted in December 2025, with prices ranging from $28.61 to $30.32 per share. Following the transaction, DuChene retains direct ownership of 2,048,895 shares. The sale occurs after a 139% one-year return for CORZ stock, though data suggests the shares may be trading above fair value with extreme volatility indicated by a beta of 5.48. Concurrently, Core Scientific has seen increased analyst coverage, with BTIG, Lucid Capital Markets, and Freedom Broker issuing ratings and price targets, alongside corporate governance updates including board appointments and the 2026 Annual Meeting of Stockholders.

Core Scientific Legal Officer Executes $292,939 Stock Sale Under Pre-Arranged Plan
CORZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Core Scientific's Chief Legal and Administrative Officer sold 10,000 shares under a Rule 10b5-1 plan, reflecting routine executive trading activity.
  • The stock has seen a 139% one-year return, but data suggests it may be overvalued with extreme volatility (beta of 5.48).
  • Analysts are highlighting Core Scientific's growth in power capacity and AI colocation potential, with multiple firms initiating coverage and raising price targets.

Todd M. DuChene, serving as the Chief Legal and Administrative Officer at Core Scientific, Inc. (CORZ), executed a sale of the company's common stock on June 22, 2026. The transaction involved the disposal of 10,000 shares, resulting in proceeds of approximately $292,939. The sales were carried out under the parameters of a Rule 10b5-1 trading plan, which DuChene established on December 5, 2025.

The filing details two distinct transactions. In the initial sale, 7,600 shares were disposed of at a weighted average price of $29.1103. These shares were sold across multiple executions with prices varying between $28.61 and $29.58. The subsequent transaction involved the sale of 2,400 shares at a weighted average price of $29.8754, with prices ranging from $29.64 to $30.32.

Post-transaction, DuChene's direct ownership in Core Scientific stands at 2,048,895 shares. The insider sale follows a substantial period of appreciation for CORZ shares, which have generated a 139% return over the past year. However, data from InvestingPro indicates that the stock may currently be overvalued, trading above its established Fair Value. Investors are advised to note that CORZ exhibits extreme volatility, characterized by a beta of 5.48, a key insight from the comprehensive Pro Research Report.

Core Scientific has recently been the subject of several analyst reports and corporate developments. BTIG raised its price target for Core Scientific to $33, maintaining a Buy rating. This adjustment followed the company's addition of approximately 1.2 gigawatts of approved power capacity, including a new 430-megawatt site in Hunt County, Texas. Lucid Capital Markets initiated coverage on Core Scientific with a Buy rating and a price target of $40, emphasizing the company's position as the first Bitcoin-to-HPC converter and its strategic lease with CRWV. Freedom Broker also initiated coverage with a Hold rating and a price target of $33, noting its potential as a high-density colocation host for AI data center capacity.

In corporate governance news, Core Scientific appointed Steve Smith to its board of directors, where he will also serve on the Nominating and Corporate Governance Committee. Smith brings over 35 years of experience and is currently the CEO of Zayo Group. Additionally, Core Scientific held its 2026 Annual Meeting of Stockholders, where five individuals were elected to the board to serve until the 2027 meeting. These developments highlight ongoing strategic and operational moves within Core Scientific.

Risks

  • The stock's high beta of 5.48 indicates extreme volatility, posing risks to investors in the technology and energy sectors.
  • Data suggests the stock may be trading above its fair value, indicating potential valuation risks for market participants.
  • Corporate governance changes and analyst rating shifts may introduce uncertainty regarding future stock performance and strategic direction.

More from Insider Trading

PTC Therapeutics Executive Offloads $1.92M in Shares Amid Strong Analyst Outlook Jun 24, 2026 Seacor Marine Executive Disposes of Shares via Pre-Arranged Plan Amid Financial Restructuring Jun 24, 2026 AMREP Executives Increase Holdings Amid Operational Improvements Jun 24, 2026 CarMax Director Peter J. Bensen Acquires $130,500 in Company Shares Amid Market Momentum Jun 24, 2026 CarMax Executive Insider Activity: CEO Keith Barr Acquires $498,247 in Company Shares Jun 24, 2026